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  Abstract	  
 
Thyroid is the endocrine gland that most frequently undergoes to congenital disorders or 
neoplastic transformation and despite its organogenesis is well characterized, molecular bases 
of early thyroid differentiation are still obscure. During last years, long non-coding RNAs 
(lncRNA) have acquired increasing relevance in many biological processes, such as 
differentiation and cancer. In E10.5 mouse thyroid bud the most enriched transcript resulted to 
be a poorly characterized lncRNA, that we named Thybe1 (thyroid bud enriched 1). Thybe1 is 
an antisense transcript of the protein-coding gene klhl14, also enriched in thyroid bud, to 
which it partially overlaps in a head-to-head arrangement. To shed light on its role, in this 
work we characterize such novel lncRNA, investigating its role in thyroid differentiation and 
its possible mechanism of action. Interestingly, we observed that Thybe1 is dramatically 
repressed during thyroid carcinogenesis, being inversely correlated with miR182a-5p 
expression, both in vitro and in vivo. Furthermore, we noted that Thybe1 expression positively 
correlates with that of Klhl14 in several cell types, suggesting that this lncRNA could also be 
able to act in cis on this target. In conclusion we describe for the first time a lncRNA involved 
in thyroid differentiation and carcinogenesis, and start to highlight its ability to act as a 
competing endogenous RNA for key developmental genes, thus identifying a novel candidate 
gene playing a role in thyroid development defects and cancer. 
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1 Background	  
1.2 Long	  non-­‐coding	  RNAs	  play	  relevant	  roles	  in	  many	  biological	  processes	  
 
1.1.1 Long	  non-­‐coding	  RNAs	  	  
 
In recent years, it has been becoming clear that transcribed but untranslated portion of 
eukaryotes genomes exceeds the protein-coding one (Maeda et al., 2006; Katayama et al., 
2005, Diez-Roux et al., 2011; Djebali et al., 2012; Costa 2010), hinting organism complexity 
could mainly depend on a RNA-mediated regulatory mechanism (Fatica and Bozzoni, 2014; 
Morlando et al., 2014). Non-coding RNA is a high wide class of molecules that are mainly 
classified according to their length in small and long non-coding RNAs (lncRNA). 
LncRNAs are RNA molecules longer than 200 nucleotides and without an evident open 
reading frame. They often are 5' capped, polyadenilated and alternatively spliced (Guttman at 
al., 2009; Derrien et al., 2012). The number and the relevance of this kind of transcripts have 
been increasing, in last years, revealing their manifold functions. Despite some common 
features, lncRNAs are a very heterogeneous group of transcripts that could be classified 
according to their genome location or their functions. 
LncRNAs could be divided in: 
◦ lincRNAs: long intergenic non-coding RNAs are located between  two protein-
coding or non-coding genes, to which it does not overlaps. 
◦ Intronic lncRNAs: These RNAs are transcribed from genes situated within the 
introns of protein-coding genes  
◦ NATs: Natural Antisense Transcripts are transcribed in the opposite sense of a 
coding gene located on the other strand. The two genes could partially overlap 
(Scheuermann and Boyer, 2013) (Figure 1). 
LncRNAs can play different roles because they can act in different ways. Being RNA 
molecules, lncRNAs are able to bind both DNA, RNA and proteins. Moreover, thanks to their 
length, these molecules can fold into secondary structures that allow them to improve the 
interaction with protein complexes and/or DNA and others RNAs (Figure 2)(Wilsuz et al., 
2009, Guttman et al., 2012; Scheuermann and Boyer, 2013; Marchese and Huarte, 2014; 
 5 
Fatica  and Bozzoni, 2014). LncRNAs can act as signals molecules, decoy, guide or scaffold 
for transcription factors or chromatin-modifying complexes, modulator of protein activity or 
splicing process, precursors of small RNAs and sponge for microRNAs (Figure 3). (Wilsuz et 
al. 2009; Wang and Chang, 2011, Marchese and Huarte, 2014; Salmena et al., 2011) Hence, 
they are implicated in transcriptional and epigenetic regulation of their targets (Costa, 2010), 
but they are also able to modulate their target levels in a post-transcriptional manner. Indeed, 
acting as a competing RNA for miRNA binding, lncRNAs can regulate the expression of 
mRNAs that are targets of the same miRNA. (Salmena et al., 2011) It was also demonstrated 
they can act in cis, to regulate neighbour genes, or in trans, on their distant targets (Zucchelli 
et al., 2015; Scheuermann and Boyer 2013; Vance et al., 2014; Boque-Sastre et al., 2015; 
Morlando et al., 2014). All these functions, from transcriptional to epigenetic control, allow 
lncRNAs to modulate their targets expression (Morris, 2009; Ørom et al., 2010), being 
involved in many important biological event, such as differentiation, development and so, 
several different diseases and cancer.  
 
 
Figure	  1.	  Representative	  class	  of	   long	  non-­‐coding	  RNAs	  based	  on	  genomic	  location.	  LncRNAs	  can	  be	  located	  
within	   introns	   of	   protein-­‐coding	   genes	   (intronic	   lncRNAs,	   on	   the	   left)	   or	   between	   two	   coding	   genes	   and	   so	  
called	   intergenic	   lncRNAs	   (lincRNAs,	   in	   the	  middle)	  without	   overlapping	  with	   their	   exons.	   Then	   they	   can	   be	  
located	  on	  the	  opposite	  strand	  of	  a	  coding	  or	  non-­‐coding	  gene	  and	  transcribed	  in	  the	  antisense	  direction	  with	  a	  
partially	  overlapping	  with	   its	  exons.	  These	  RNAs	  are	  called	  Natural	  Antisense	  Transcripts	   (NATs,	  on	  the	  right)	  
(Scheruermann	  and	  Boyer,	  2013)	  
	  
	  
	  
	  
 6 
 
Figure	  2.	  Global	  mechanisms	  of	   lncRNAs.	  Thanks	  to	  their	  structure	  lncRNAs	  are	  able	  to	  interact	  with	  proteins	  
(left),	  bind	  DNA	  (middle)	  and	  RNA	  molecules	  such	  as	  mRNAs	  or	  microRNAs	  (right).	  (Scheruermann	  and	  Boyer,	  
2013)	  
 
 
Figure	  3.	  Representative	  scheme	  of	  lncRNAs	  functions.	  Transcription	  from	  an	  upstream	  non-­‐coding	  promoter	  
(orange)	  can	  negatively	  (1)	  or	  positively	  (2)	  affect	  the	  expression	  of	  downstream	  gene	  (blue)	  by	  inhibiting	  Pol	  II	  
recruitment	   or	   inducing	   chromatin	   remodelling	   respectively.	   (3)	   An	   antisense	   transcript	   (purple)	   is	   able	   to	  
hybridize	  to	  the	  overlapping	  sense	  transcript	  (blue)	  and	  block	  recognition	  of	  the	  splice	  sites	  by	  the	  spliceosome,	  
thus	  resulting	   in	  an	  alternatively	  spliced	  transcript.	   (4)	  Alternatively,	  hybridization	  of	  the	  sense	  and	  antisense	  
transcripts	   can	   allow	   Dicer	   to	   generate	   endogenous	   siRNAs.	   By	   binding	   to	   specific	   protein	   partners,	   a	  
noncoding	  transcript	  (green)	  can	  modulate	  the	  activity	  of	  the	  protein	  (5),	  serve	  as	  a	  structural	  component	  that	  
allows	  a	   larger	  RNA–protein	  complex	  to	   form	  (6),	  or	  alter	  where	  the	  protein	   localizes	   in	  the	  cell	   (7).	   (8)	  Long	  
ncRNAs	  (pink)	  can	  be	  processed	  to	  yield	  small	  RNAs,	  such	  as	  miRNAs	  (Wilsuz	  et	  al.,	  2009)	  
	  
 
1.2.1 Long	  non-­‐coding	  RNAs	  and	  organ	  differentiation	  
 
Long non coding RNAs have been described to be expressed at lower levels than protein-
coding genes and in a more tissue and cellular specific manner (Cabili et al., 2011; Morlando 
et al., 2014; Marques and Ponting, 2009; Boque-Sastre et al., 2015; Vučićević D, 20015). 
This specificity suggests their involvement in determining cell fate, acting as regulators of 
many differentiation processes (Flynn and Chang, 2014). Some lncRNAs operate modulating 
their targets transcription. For example, the lncRNAs Braveheart and Fendrr were described 
to be specifically required for cardiomyocytes development, acting as a decoy for the 
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Polycomb repressive complex PCR2 (Scheuermann and Boyer, 2013). PCR2 decoy is 
exploited also by the lncRNA-N1 and lncRNA-N3 in driving neurogenesis. Neurogenesis is 
the differentiation process that implicates the major number of lncRNA, probably for the high 
number of different cell type it has to generate (Fatica and Bozzoni, 2014). One of the central 
lncRNA involved in this process is Evf2 (also known as Dlx6os1). It negatively regulates, in 
cis, Dlx6 expression whereas recruits, in trans, the transcription activator factor DLX2 and the 
repressor MECP2 to regulate the expression of Dlx5 and Gad1. Evf2 mutants show defects in 
synaptic inhibition, hinting the important role this lncRNA play in neuronal activity (Feng et 
al., 2006) 
However, despite transcriptional regulation is a well described and very common mechanism 
of action for lncRNAs, these molecules work in many other manners. The lncRNA TINCR, 
for example, promotes keratinocytes differentiation stabilizing the targeted mRNAs, such as 
keratin 80 (Fatica and Bozzoni, 2014) 
During myogenesis, instead, linc-MD1 competes for mir133b and mir135 binding with the 
key myoblast differentiation factors MALM1 and MEF2C. Through this miRNAs sponge 
activity, linc-MD1 presence increases MALM1 and MEF2C expression, improving 
myogenesis (Cesana et al., 2011; Twayana et al., 2013). 
This evidence highlights the heterogeneous range of roles lncRNAs are able to play and their 
relevance in specific tissue differentiation programs. 
 
1.2.2 Long	  non-­‐coding	  RNAs	  in	  cancer.	  
 
Considering their involvement in differentiation processes, it was rational to conjecture that 
lncRNAs were also implicated in the loss of differentiation and then in carcinogenesis. 
Indeed, several lncRNAs have been described as involved cancer onset and/or progression. In 
AML cells, for example, many lncRNAs resulted involved in granulocytic differentiation 
(Hughes et al., 2014). Among these, UCA1 was classified as oncogenic because it supports 
the proliferation of AML C/EBPα mutated cells by repressing the cell cycle regulator p27kip1 
(Hughes at al., 2015). Many lncRNAs are described as up-regulated in different type of 
cancer, causing the repression of their targets interacting with the Polycomb repressive 
complex PRC1/2. Among these, TUG1, for example, is up-regulated in lung cancer; 
MALAT1 is associated with malignancy of liver, breast and colon cancer  (Huarte, 
2015,Wang et al., 2017) and HOTAIR, is known to promote metastasis in liver, breast and 
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lung cancers, being implicated in epithelial-to mesenchymal transition (EMT)(Wang et al., 
2017, Huarte, 2015; Gibb et al., 2011).  
However, interacting with protein complexes is not the only mechanism through which 
lncRNAs modulates cancer aggressiveness.  Indeed, the lncRNA ZFAS1 competes for the 
miR-150-5p binding to regulate Sp1 expression in ovarian cancer. ZFAS1 dysregulation has 
been observed in breast, colorectal and gastric cancer and hepatocellular carcinoma and it is 
associated with a poor prognosis of ovarian cancer (Xia et al., 2017). The miRNA-mediated 
mode of action was also exploited by lncRNA HULC that is high expressed in primary liver 
tumors and is considered a biomarker of liver cancer (Gibb et al., 2011). As well as ZFAS1, 
HULC, MALAT1 and the antisense transcript TRPM2, together with PCA3, are currently 
used as prognostic markers of liver, lung and prostate cancer respectively (Huarte 2015; Gibb 
et al., 2011; Xia et al., 2017; Orfanelli et al., 2015). Moreover, the NAT of Zeb2 gene has 
been described to be associated with cancer with low levels of E-cadherin. This natural 
antisense transcript positively regulates the transcriptional repressor Zeb2, leading to E-
cadherin reduction and so promoting EMT (Sanchez and Huarte, 2013).  
Given their overexpression and functions observed in cancer, these lncRNAs are currently 
considered as oncogenic RNAs, whereas lncRNAs as GAS5 and XIST are classified as tumor 
suppressors. Indeed, XIST expression is considerably reduced in breast cancer comparing 
with normal tissue and GAS5 is down-regulated in multiple cancers, such as breast, 
colorectal, lung, prostate and ovarian cancers. It is involved in cell cycle regulation, as 
described in neuroblastoma and acts as sponge for miR-21 in breast cancer (Wang et al., 
2017; Li et al., 2016; Mazar et al., 2016).  
Because of their regulatory functions, lncRNAs often mark the early phases of carcinogenesis, 
so they could be very useful in the prognosis of cancer progression but also in developing new 
therapeutic approaches. Indeed, given the relevance these molecules have been acquiring in 
cancer biology in last years, the interest in exploiting lncRNAs as new therapeutic targets is 
also increasing. Several strategies have been tested to target the RNA of interest, such as 
nanoparticles, peptides-mediated delivery and CRISP/Cas9 genome editing. However, 
handling RNAs in vivo presents many hurdles that it is need to overcome, such as the innate 
immunity, the target selectivity and the delivery (Lavorgna et al., 2016). However, 
considering the increasing resistance different types of cancer show to traditional care, 
improving and making all these new approaches an actual therapeutic strategy would 
represent an important resource in cancer treatment. 
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1.3 Thyroid	  gland	  	  
1.3.1 Thyroid	  gland	  differentiation	  
 
Thyroid is the main endocrine gland, responsible for the synthesis of thyroid hormones T3 
and T4 that play a central role in metabolism regulation. To study this its anatomy, 
functioning and development, mouse is the ideal model because of the similarity of adult 
mouse and human thyroid anatomy and the embryonic development of the gland (Figure 3) 
(Fagman and Nilsson, 2010; Fernández et al., 2014).  
Thyroid is mainly made of two cells types: thyroid hormones-producing follicular cells 
(TFCs) and calcitonin-producing parafollicular or C cells. TFCs represent the most numerous 
cell population in the thyroid gland and are organized in a follicular structure that holds 
Thyroglobulin-containing colloid. Instead, C cells are disseminated within the gland, mostly 
in parafollicular position (De Felice and Di Lauro, 2004). TFCs cells are characterized by the 
combined expression of the transcription factors Hhex, Ttf1, Pax8 and Foxe1 that are known 
to cooperate only in thyroid (De Felice and Di Lauro 2004; Fagman and Nilsson, 2010). 
Follicular cell precursors begin to express these factors at E9 of mouse embryo development, 
concurrently with thyroid determination beginning at E8-8.5, when the first thyroid anlage is 
identifiable (De Felice and Di Lauro 2004; Fagman and Nilsson, 2010; Fernández et al., 
2014). At E9.5, the thyroid anlage forms the thyroid bud that at E10 begins to sever from 
pharyngeal floor to reach the trachea at E13.5 (De Felice and Di Lauro, 2004; Fernández et 
al., 2014). Functional differentiation starts at E14.5 with the expression of thyroglobulin (TG) 
followed the activation of the other proteins required for thyroid hormone synthesis: 
thyroperoxidase (TPO) and thyrotropin receptor (TSHr) (Missero et al., 1998; Fernández et al, 
2014). However, T3 and T4 synthesis begins at E16.5, only after the completion of migration 
and follicular organization and the expression of the sodium/iodide symporter (NIS) that 
occur between E15 and E16 (De Felice and Di Lauro, 2004; Fernández et al. 2014).  
However, whereas thyroid organogenesis is well characterized, very little is known about the 
first steps of thyroid commitment. Indeed, FTCs originate form endodermal cells of the 
midline of the foregut such as, liver, pancreas and lung primordia and it is still unclear how a 
subset of endoderm cells adopts a thyroid fate (De Felice and Di Lauro 2004; Fagman and 
Nilsson, 2010; Fagman and Amendola et al., 2011). 
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1.3.2 Thyroid	  cancer	  
 
Thyroid cancer is the most common endocrine malignancy and one of the few cancers whose 
incidence has been increasing worldwide. Interestingly, it is described as the cancer with the 
greatest genetic component among not hereditary cancers. Indeed, among these ones, thyroid 
cancer shows the highest risk in first-degree relatives of probands. 
Most of thyroid cancers originate from epithelial follicular cells and are well-differentiated 
tumors. They usually have a good prognosis and survival rates more than 95% at 20 years 
(Tuttle et al. 2010). Neoplastic transformation of thyroid follicular cells can give rise to three 
main histotypes of thyroid carcinomas: papillary thyroid carcinoma (PTC), follicular thyroid 
carcinoma (FTC) and anaplastic thyroid carcinoma (ATC). PTC and FTC are well-
differentiated tumors and PTC is the most frequent, consisting in 85-90% of thyroid cancer 
cases. On the contrary, ATC is a highly aggressive undifferentiated tumor and is considered to 
develop from differentiated ones. It represents less of 2% of thyroid cancers, but about 40% 
of thyroid cancer deaths   (Nikiforov et al. 2009; Katoh et al., 2015). 
Genetic alterations causing thyroid cancer are well known and include point mutations and 
gene translocations. The first affect common oncogene such as serine/threonine kinases RAS 
and BRAFs, whereas chromosomal translocations occur in about 60% of PTC and 30% of 
FTC. Thyroid epithelium seems to have a propensity for chromosomal rearrangement (Alsina 
et al., 2017). 
N-RAS and AKT mutations and PAX8/PPARγ rearrangement are most frequently found in 
FTC.  BRAFV600E mutation and RET/PTC rearrangement are the main alterations leading to 
PTC, often followed by a secondary MET overexpression that promotes cell motility and 
invasion. TG mutations and NTRK1 rearrangements with different genes are also identified in 
PTC. PTEN down-regulating and TP53 up-regulating alterations characterize ATC, as well as 
mutations in CTNNB1 gene, involved in de-differentiation process of thyroid carcinoma and 
used as biomarker of tumor progression (Katoh et al., 2015; Alsina et al., 2017). Moreover, 
despite ATC shows a low incidence, it is lethal in the most of cases because of distant 
metastasis and its refractoriness against treatments (Katoh aet al. 2015). Hence, it is important 
to identify the factors involved in thyroid carcinoma de-differentiation that could early detect 
tumors with poor prognosis. 
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2 Aim	  
 
Molecular mechanisms underlying early thyroid specification are still unclear. It is known that 
thyroid primordium expresses the transcription factor Ttf1 starting from E9.5 of mouse 
embryo development, but only one day later it is possible to morphologically recognize 
thyroid bud. So, to shed lights on early thyroid differentiation, our group performed a 
transcriptome analysis on E10.5 thyroid bud that picked up the transcripts enriched in this bud 
compared with the whole embryo.  Among these, a poorly characterized gene, reported as a 
long non-coding RNA, emerged as the most enriched one (Figure 4) (Fagman and Amendola 
et al., 2011). Given these preliminary data, the main aim of my PhD work has been to 
characterize this lncRNA, analyzing its role in thyroid gland to understand its possible 
involvement in the regulation of thyroid differentiation both in normal and in neoplastic cells, 
and investigating its possible modes of action. The results of such work could add a rawplug 
leading to the final goals of understanding of what determines thyroid fate of some 
endodermal cells and/or which are the still unknown genetic factors involved in thyroid 
cancer susceptibility. Indeed, the relevance that this RNA could have in thyroid differentiation 
could open the way to a new approach in studying thyroid development and function. 
 
 
 
Figure	  4.	  The	  thyroid	  bud	  most	  enriched	  gene	  is	  a	  poorly	  characterized	  gene.	  A	  transcriptome	  analysis	  of	  
thyroid	  bud	  was	  performed	  at	  E10.5	  of	  mouse	  embryo	  development.	  The	  results	  was	  a	  list	  of	  thyroid	  bud	  
enriched	  genes	  represented	  in	  A.	  Among	  these,	  a	  poorly	  characterized	  gene	  emerged	  as	  the	  most	  enriched	  one	  
(red	  rectangle).	  Its	  enrichment	  was	  confirmed	  by	  in	  situ	  hybridization	  analysis	  shown	  in	  B.	  (Fagman	  and	  
Amendola	  et	  al.,	  2011)	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3 Materials	  and	  Methods	  
 
3.1 	  RNA	  analysis	  
3.1.1 Quantitative	  Real-­‐Time	  PCR	  	  
 
Total RNA was isolated form cultured cells and mouse thyroids using Trizol (Sigma Aldrich) 
reagent according to manufacturer’s specifications. Total cDNA was generated with Super 
Script III Reverse Transcriptase (Thermo Fisher Scientific), according to manufacturer’s 
specifications. Real-Time PCR on total cDNA was performed with SYBR-Green mix (Bio-
Rad) using gene specific oligos: 
 
Pan Thybe1 F: GGCTCCTCTCCACTCACTTTC 
Pan Thybe1 R: TCAGCTCAGCAGCGAAGTC 
T1humanF: CAGCACGGACATCTGGAAGA 
T1humanR: GCCTCAGCCGCCACTTTG 
Pax8 F: GCCATGGCTGTGTAAGCAAGA 
Pax8 R: GCTTGGAGCCCCCTATCACT 
Foxe1 F: AAGCCGCCCTACAGCTACATCG 
Foxe1 R: AACATGTCCTCGGCGTTGGG 
TG F: CATGGAATCTAATGCCAAGAACTG 
TG R: TCCCTGTGAGCTTTTGGAATG 
NIS F: TCCACAGGAATCATCTGCACC 
NIS R: CCACGGCCTTCATACCACC 
TSHR F: TCCCTGAAAACGCATTCCA 
TSHR R: GCATCCAGCTTTGTTCCATTG 
TTF1 F: CTACTGCAACGGCAACCTG 
TTF1 R: CCCATGCCATCATATATTCAT 
Bcl2 F: GACGCGAAGTGCTATTGGTAC 
Bcl2 R: CTCAGGCTGGAAGGAGAAGAT 
Klhl14 F: CGATGACAGCATTTATCTAGTTGG 
Klhl14 R: GCAGATTGTAGAGGACTTGTAGGC 
HK14 F: GACGCCATGAACTACCACCT 
HK14i R: GCCCTCCAACCAATAACAGC 
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Ciclofillin F: GGATTCATGTGCCAGGGTGG 
Ciclofillin R: CACATGCTTGCCATCCAGCC 
Abelson F: TCGGACGTGTGGGCATT 
Abelson R: CGCATGAGCTCGTAGACCTTC 
Tubulin a1a F: CAACACCTTCTTCAGTGAGACAGG 
Tubulin a1a R: TCAATGATCTCCTTGCCAATGGT 
18S F: CGGCTACCACATCCAAGGAA 
18S R: GGGCCTCGAAAGAGTCCTGT 
 
MiRNA-specific Reverse Transcriptase and Real-Time PCR were carried out using TaqMan®  
MicroRNA Reverse Transcription kit, TaqMan®  MicroRNA Assays and TaqMAn® 
Universal PCR MasterMix, No AmpErase® UNG (Applied Biosystems) according to 
manufacturer’s specification. 
3.1.2 In	  situ	  Hybridization	  	  
 
Embryos and organs were fixed in 4% PFA, dehydrate and paraffin embedded according the 
following protocol: 
• 4% depcPFA 4°C o.n. 
• 2X Saline RT 
• Saline/EtOH 96% RT 
• EtOH 70% RT 
• EtOH 70% 4°C o.n. 
• EtOH 85% RT 
• EtOH 96% RT 
• EtOH 100 RT 
• EtOH 100% 4°C o.n. 
• 2X Xilene RT 
• Xilene/paraffin 60°C 
• 3X paraffin 60°C 
The period of RT and 60°C steps is determined according to the size of the processed sample. 
Paraffin embedded samples were sliced in 7µm sections and analyzed. To perform the in situ 
hybridization, the sections were deparaffinized in xylene and rehydrated with EtOH 100% to 
EtOH 50%. After rehydration, the hybridization was performed as described in Fagman and 
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Amendola et al., 2011, using specific probes for Thybe1 and Klhl14 amplified from adult 
mouse thyroid cDNA using the following oligos: 
Thybe1 sp6: GGCTGAACAGGAAGGGACCCT 
Thybe1 T7: CAGATCACAGCTAAGAAAAAAGC 
K14 F: GAGGATACAGCTGGAGTATGGG 
K14 R: GAGCTGAAGAGCAATAGGGTGT 
 
3.2 	  Transcripts	  mapping	  
 
cDNA form adult mouse thyroid and FRTL-5 were amplified with the oligos representing the 
ends obtained through RACE experiments and the 5’ oligo included the upstream CAGE site 
reported in UCSC: 
Thybe1 CAGE: CGCGTACTGCATGCGGGTCTCA 
Thybe1 5’RACE: GAGAGAGGAACAACAATCAAGGC 
Thybe1 3’ RACE: GGGGATTAGAGTTTATTTTTGTCATCTC 
The fragments obtained were blasted against Mouse and Rat genomes reported in NCBI and 
ENSEMBL. 
 
 
3.3 	  Cell	  culture	  and	  transfection	  
 
FRTL-5, ERRASV12FRTL-5 and RASV12FRTL-5 were grown in Coon’s modified F12 
medium (Euroclone) supplemented with 5% calf serum (Hyclone Thermo Fisher Scientific) 
and six hormones as described in De Vita et al. (2005). Locked nucleic acid oligos, miRNA 
mimics and plasmid DNA were transfected using Lipofectamine 2000® (Thermo Fisher 
Scientific) according with manufacturer’s specifications. Tamoxifene, MAPK and PI3K 
inhibitors (U06126 (Biomol BPS-27012) and LY294002) were added to culture medium at 
0.4 nM, 0.25nM and 0.75 nM respectively. 
LNA panTb1 was designed through Exiqon tool that generated the following sequence and 
has ready negative controls: 
LNA panTb1: AAGTGAGTGGAGAGGA 
LNA negative control: AACACGTCTATACGC 
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3.4 	  Protein	  analysis	  
3.4.1 Protein	  Extraction	  and	  Western	  Blot	  
 
Total proteins were extracted using a lysis buffer made of NaCl 150mM, Tris HCl 50mM, 
MgCl2 5mM, Na deoxycolate 0.5 %, SDS 0.1%, Triton X-100 1%. To this buffer were added 
DTT 0.1 mM, PMSF 0.5 mM, proteinase inhibitor cocktail (Sigma Aldrich P8340) and 
phosphatase inhibitor (Sigma Aldrich P0044). 20µg were loaded for western blot analysis. 
Immunoblots were incubated with the following antibodies: anti-Pax8 (home-made), anti-
Bcl2 (Santa Cruz 7382), anti-pAKT (cell signaling 9275), anti pERK (cell signaling 9101), 
anti-AKT (cell signaling 9272), anti-ERK (cell signaling 9102) and anti-GAPDH (Immuno 
Chemical G4-C5-N). 
 
3.4.2 Immunohistochemistry	  
 
7µm sections were obtained, deparaffinized and rehydrated as described for ISH. 
The sections were permeabilized with 5’ PBS-0.2% triton, washed 2X 5’ PBS and they 
underwent unmasking treatment in citrate buffer (0.01M pH6) 15’ in the microwave. 
Endogenous peroxidases were then saturated with methanol and 1.5% oxygen peroxide and 
tissues permeabilized with 5’ PBS-0.2% triton, washed 2X 5’ PBS and blocked in blocking 
solution (5% Normal goat serum (Vector Laboratories S-1000), 3% BSA, 20mM MgCl2, 
0.3% tween20 in PBS) 1h at room temperature. Primary antibody (α-klhl14 Abcam 49353) 
was used 1:200 in blocking solution overnight at 4°C. The sections then underwent to the 
following protocol: 
 5’ PBS-0.2% triton, 2X 5’ PBS, 1h secondary antibody (biotinilated α-rabbit IgG 
(H+L)Vector Laboratories BA-1000) 1:200 in blocking solution at room temperature,  5’ 
PBS-0.2% triton, 2X 5’ PBS, 30’ ABC (Vector Laboratories SK-4000) RT, 5’ PBS-0.2% 
triton, 3X 5’ PBS, 2’ DAB substrate (Vector Laboratories SK-4100). 
The samples were then de-hydrated as described for the inclusion process and cover with 
cover glasses using Eukitt mounting solution (Eukitt® Quick-hardening mounting medium, 
Sigma-Aldrich 03989).  
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3.5 	  Plasmids	  
 
Specific primers were used to amplify mouse Thybe1 Rik 04 from adult mouse thyroid: 
Thybe1 5’RACE: GAGAGAGGAACAACAATCAAGGC 
Thybe1 3’ RACE: GGGGATTAGAGTTTATTTTTGTCATCTC 
KpnI and XbaI sites, at 5’ and 3’ end, respectively, were included in these primers. The 
amplified product was sucloned into the eukaryotic expression vector pCEFL 
 
 
3.6 	  Mice	  treatment	  
 
Animals were kept in an animal house under controlled conditions of temperature, humidity, 
and light and were supplied with standard or implemented food and water ad libitum. Tg-
rtTA-TetO-BRafV600E transgenic mice were fed with a 25000mg/kg Doxycycline 
supplemented fodder for one week.  TetO-BRafV600E and Tg-rtTA transgenic mice arrived 
from Fagin’s group in New York for a scientific collaboration and were crossed to obtain the 
double transgenic mice Tg-rtTA; TetO-BRafV600E to treat. All animal experiments were 
performed in accordance with regulations and guidelines of Italy and the European Union and 
were approved by the local ethical committee. 
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4 Results	  
 
4.1 	  Thybe1	  gene	  is	  expressed	  in	  different	  transcripts	  
 
Thybe1 is a poorly characterized gene reported in genomic databases as long non-coding 
RNA. We looked at mouse and rat Thybe1 locus in several databases such as NCBI, UCSC 
and Ensembl. In mouse it is named 4930426D05Rik and maps to 18qA2 (Figure 5A), while in 
rat it is named LOC102555023 and maps to 18p12 (Figure 5B).  Interestingly, in both 
genomes Thybe1 partially overlaps with the protein-coding gene Klhl14 in a head-to-head 
antisense arrangement (Figure 5A,B). Such overlap with Klhl14 is conserved in a wide range 
of vertebrate genomes, including humans (data not shown).   
It is worth noting that different transcripts are reported for this gene in both mouse and rat. As 
shown in Figure 2A, mouse Thybe1 presents four transcripts called as 4930426D05Rik 01, 
02, 03 and 04. These transcripts differ for the transcription start site and/or the exons, mainly 
at the 5' moiety, whereas all except Rik04 share three regions (Figure 6 orange, pink and 
green rectangles). As we were interested in Thybe1 function in thyroid, we decided to 
characterize which of the reported transcripts were expressed in this gland. To this purpose we 
amplified ad sequenced several transcripts from adult mouse thyroid cDNA. To map 5' and 3' 
ends of thyroid isoforms we performed RACE experiments (data not shown) that identified a 
polyadenylated 3' end (Figure 6 green rectangle) but did not give unambiguous information 
about 5' end. For this reason we looked for annotated CAGE sites in UCSC database. Then 
starting form Race identified ends and the most upstream CAGE site reported, we amplified 
and sequenced several fragments. Through this analysis, we revealed all the transcripts 
reported, except Rik02, exist and are expressed in thyroid. Moreover, we identified three 
differently spliced transcripts that have not been previously annotated (Figure 6). 
The same analysis was performed on FRTL-5 rat thyroid follicular cells cDNA, to 
characterize rat Thybe1 transcripts. Two different transcripts are currently reported for rat 
Thybe1 (Figure 7A), with different 5' ends and exon splicing, sharing the last two exons 
(Figure 3 red and blue rectangles). Starting from the reported ends we amplified and 
sequenced two transcripts that do not correspond to the reported ones (Figure 7). We will 
refer to these transcripts as long and short Thybe1. These results reveals that Thybe1 is 
expressed in mouse and rat thyroid with multiple transcripts, some of which are novel 
isoforms not reported in genomic databases. 
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Figure	  5.	  Thybe1	  maps	  on	  chromosome	  18	  both	  in	  mouse	  and	  in	  rat.	  NCBI	  Thybe1	  locus	  representation	  shows	  	  
the	  long	  non-­‐coding	  gene,	  indicated	  by	  the	  red	  arrow,	  is	  situated	  on	  chromosome	  18qA2	  in	  mouse	  (A)	  and	  on	  
chromosome	  18p12	  in	  rat	  (B),	   in	  the	  regions	  pointed	  out	  by	  blue	  stripe.	   In	  both	  species	  Thybe1	  is	   located	  on	  
the	   plus	   strand	   and	   shows	   a	   partially	   overlapping	   head-­‐to-­‐head	   arrangement	   with	   the	   protein-­‐coding	   gene	  
Klhl14	  on	  the	  opposite	  strand	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Figure	  6.	  Mouse	  Thybe1	  has	  different	   transcripts.	  As	   reported	   in	   the	  Ensembl	  representation,	   four	  different	  
transcripts	   are	   reported	   for	   mouse	   Thybe1	   that	   differ	   for	   the	   transcription	   start	   site	   and	   are	   differentially	  
spliced,	  but	  share	  three	  regions	   indicated	  by	  orange,	  pink	  and	  green	  rectangles.	  Starting	  from	  CAGE	  site	   (red	  
rectangle)	  and	  5’	  and	  3’	  ends	  identified	  by	  RACE	  (blue	  and	  green	  rectangles),	  we	  amplified	  several	  transcripts	  
from	  adult	  mouse	  thyroid	  cDNA.	  Their	  sequencing	  revealed	  that	  mouse	  thyroid	  expresses	  different	  transcripts:	  
the	   reported	   rik03,	   rik04	   and	   rik05,	   but	   not	   rik02	   and	  other	   three	  not	   annotated	   isoforms,	   indicated	  by	   red	  
arrows.	  
	  
	  
	  
Figure	   7.	   Rat	   Thybe1	   has	   different	   transcripts.	   Rat	   Thybe1	   presents	   three	   transcripts	   with	   different	  
transcriptional	  stat	  site	  and	  exon	  splicing	  but	  with	  shared	  last	  two	  exons	  (red	  and	  blue	  rectangles),	  except	  for	  
transcript	  201.	  Amplified	  and	  sequenced	  fragments,	  from	  rat	  thyroid	  follicular	  cells	  FRTL-­‐5	  cDNA,	  were	  blasted	  
to	  rat	  genome.	  The	  two	  transcripts	  identified	  in	  FRTL-­‐5	  do	  not	  correspond	  to	  anyone	  of	  the	  annotated	  ones	  and	  
differ	  for	  5’	  regions,	  preserving	  the	  conserved	  region.	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4.2 Thybe1	  is	  expressed	  in	  thyroid	  from	  embryo	  to	  adult	  life.	  
 
Since Thybe1 was found out looking for genes enriched in thyroid bud at E10.5 of mouse 
embryo development, we assayed its expression form this stage forwards in thyroid 
organogenesis and differentiation. We performed in situ hybridization (ISH) at E9.5, E10.5, 
E14.5 and E18.5 (Figure 8A) showing that Thybe1 is already expressed at E9.5, the very early 
stage of thyroid specification and its thyroid expression is maintained until later stages of 
thyroid development. Given this evidence, we wondered if its strong thyroid expression is 
also retained in adult life. To answer this question, we evaluated Thybe1 presence in mouse 
adult tissues, through qRT PCR (Figure 8B) and in situ hybridization (Figure 8C) analyses. 
QRT PCR gave us an idea of Thybe1 dealing out among adult tissues, showing that it is 
expressed in several organs such as kidney, spleen, testis and above all, thyroid gland. 
However, qRT PCR considers the whole organ, overlooking the differences between different 
types of cells that constitute that organ. This technical limit could lead to underestimating 
Thybe1 presence in given cell types. In situ hybridization, instead, let us to clearly understand 
the lncRNA distribution in specific cellular types. ISH performed on adult mouse organs 
revealed that Thybe1 is expressed in the cortex of kidney and in the white pulp of the spleen. 
With respect to the brain, its expression is restricted mostly in the hippocampus and the 
cortex, whereas in thyroid is highly expressed in follicular cells (Figure 8C). Then we looked 
for data about Thybe1 human expression profile. Gtex annotations in UCSC database report 
that the lncRNA is expressed in kidney, spleen, as observed in mouse, and that its enrichment 
in thyroid is confirmed also in humans (Figure 9) (https://genome.ucsc.edu/cgi-
bin/hgGene?hgg_gene=uc060ohv.1&hgg_prot=ENST00000426194.1&hgg_chrom=chr18&h
gg_start=32769794&hgg_end=32774413&hgg_type=knownGene&db=hg38&hgsid=577587
793_hj7rmd9LRdwjB5zqKr2VTfxokw0d ). 
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Figure	  8.	  Thybe1	  is	  expressed	  in	  thyroid	  from	  embryo	  to	  adult	  life.	  Thybe1	  in	  situ	  hybridization	  (A)	  shows	  that	  
Thybe1	  is	  strongly	  expressed	  in	  thyroid	  bud	  from	  E9.5	  of	  mouse	  embryo	  development	  to	  later	  prenatal	  stage.	  
Quantitative	   real	   time	   PCR	   (B)	   on	   adult	  mouse	   tissues	   reveal	   that	   Thybe1	   is	   expressed	   in	   several	   tissues,	   in	  
particular	   in	   kidney	   and	   spleen,	   showing	   an	   enrichment	   mainly	   in	   thyroid	   gland.	   In	   situ	   hybridization	   (C)	  
confirms	   these	   data,	   revealing	   that	   Thybe1	   is	   expressed	   in	   specific	   areas.	   In	   kidney	   Thybe1	   is	   expressed	   in	  
cortex.	  In	  spleen	  the	  lncRNA	  expression	  is	  restricted	  to	  the	  white	  pulp	  (WP);	  whereas	  in	  brain	  its	  expression	  is	  
prevailing	  in	  cortex	  and	  hippocampus.	  In	  thyroid	  Thybe1	  shows	  a	  strong	  expression	  in	  follicular	  cells.	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Figure	  9.	   Thybe1	  expression	  profile	   is	   conserved	   in	  human.	  Bioinformatic	  analysis	   from	  Gtex	  RNA-­‐seq	   	  data	  
shows	   that	   human	   Thybe1	   is	   expressed	   in	   kidney,	   spleen,	   testis,	   but	   it	   is	   primarily	   expressed	   in	   thyroid	  
(https://genome.ucsc.edu/cgi-­‐
bin/hgGene?hgg_gene=uc060ohv1&hgg_prot=ENST00000426194.1&hgg_chrom=chr18&hgg_start=32769794
&hgg_end=32774413&hgg_type=knownGene&db=hg38&hgsid=577434493_IhpdLNxXhHdz9vkXi0a46pk2afPA).	  
	  
	  
 
4.2.1 Thybe1	  overlapping	  gene	  Klhl14	  shows	  a	  similar	  expression	  trend	  
 
An interesting feature of Thybe1 locus is its head-to-head overlapping arrangement with the 
protein-coding gene Klhl14 on the opposite strand (Figure 5). This arrangement allows to 
classify this lncRNA as NAT (Natural Antisense Transcript). NATs are described to be able 
to positively or negatively regulate the associated protein-coding gene (Zucchelli et al, 2015), 
leading to either a comparable or an opposite expression profile between the two genes 
(Wilsuz et al., 2009; Scheuermann and Boyer, 2013; Boque-Sastre et al., 2015). For this 
reason we investigated Klhl14 expression profile and compared it to that of Thybe1. Since 
Klhl14 resulted also enriched in thyroid bud at E10.5 (Fagman and Amendola et al., 2011), 
we decided to follow its expression during thyroid development. We performed an IHC on 
mouse embryos from E10.5 forward, observing Klhl14 thyroid expression is maintained 
during embryo development (Figure 10A), as already observed for Thybe1 (Figure 8A). Then 
we evaluated Klhl14 levels in adult mouse tissues through qRT PCR (Figure10B), noting that 
it is expressed in several adult tissues such as kidney, heart, brain, by also retaining a strong 
thyroid expression. In situ hybridization on (Figure 10C) reveals that Klhl14 RNA is 
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considerably expressed in thyroid follicular cells and it is located in kidney cortex, medulla 
and calyces, in the white pulp of the spleen and in the hippocampus and cortex in the brain , 
similarly to what described for Thybe1 (Figure 8C). We also looked for this protein coding 
gene data in human gene expression databases. Gtex annotations, from UCSC database, 
reporting Klhl14 as mainly expressed in kidney, brain and thyroid 
(Figure11)(https://genome.ucsc.edu/cgi-
bin/hgc?hgsid=577587793_hj7rmd9LRdwjB5zqKr2VTfxokw0d&c=chr18&l=32672670&r=3
2773062&o=32672670&t=32773062&g=gtexGene&i=KLHL14. All these data show that 
Thybe1 and Klhl14 have a similar expression profile, so it is likely that Thybe1 could 
positively regulate Klhl14. 
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Figure	   10.	   Klhl14	   expression	  profile	   is	   similar	   to	   Thybe1.	  Klhl14	   IHC(A)shows	  Klhl14	   is	   strongly	  expressed	   in	  
thyroid	  bud	  from	  E10.5	  of	  mouse	  embryo	  development	  to	  later	  prenatal	  stage.	  Quantitative	  real	  time	  PCR	  (B)	  
on	  adult	  mouse	  tissues	  reveals	  that	  klhl14	  is	  expressed	  in	  several	  tissues	  such	  as	  kidney,	  lung,	  heart,	  spleen	  and	  
brain,	   evidencing	   a	   strong	   thyroid	   expression.	   In	   situ	   hybridization	   (C)	   shows	   Klhl14,	   as	   well	   asThybe1,	   is	  
expressed	  in	  specific	  cellular	  types.	  In	  kidney	  it	  is	  expressed	  in	  cortex,	  medulla	  and	  also	  calyces	  (Cl).	  In	  spleen	  
Klhl14	  is	  expressed	  in	  the	  white	  pulp.	  Brain	  shows	  klhl14	  enrichment	  in	  cortex	  and	  hippocampus	  and	  follicular	  
thyroid	  cells	  expression	  was	  confirmed.	  
	  
	  
Figure	  11.	  Klhl14	  expression	  profile	   is	   conserved	   in	  human.	  Bioinformatic	  analysis	   from	  Gtex	  RNA-­‐seq	   	  data	  
shows	   that	   human	   Klhl14	   is	   expressed	   in	   kidney	   and	   spleen	   but	   it	   is	   primarily	   expressed	   in	   thyroid	   gland	  
(https://genome.ucsc.edu/cgi-­‐
bin/hgchgsid=577434493_IhpdLNxXhHdz9vkXi0a46pk2afPA&c=chr18&l=32672670&r=32773062&o=32672670
&t=32773062&g=gtexGene&i=KLHL14).	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4.3 	  Thybe1	  is	  required	  for	  thyroid	  differentiation	  in	  vitro	  
 
To investigate if Thybe1 plays a role in thyroid differentiation we down-regulated its 
expression in rat thyroid follicular cells FRTL-5. FRTL-5 are adult wild type thyroid 
epithelial cells that express all thyroid differentiation markers (Fusco A et al.,1987; 
Berlingieri et al., 1988), including Thybe1, as it is shown in Figure 12B. We used locked 
nucleic acid oligos (LNAs) to obtain Thybe1 knockdown and then we measured thyroid 
marker levels by quantitative real time PCR. LNAs longRNA GapmeRs are DNA antisense 
oligonucleotides in which the ribose ring is “locked” by a methylene bridge. These molecules 
are complementary to their RNA target and when introduced into cells, they sequester their 
target RNA in highly stable DNA: RNA heteroduplexes, leading to RNase H-mediated target 
degradation. An LNA targeting the common region (LNA pan Tb1) was used to repress all 
Thybe1 transcripts (Figure 12A,B). Thybe1 knocking-down causes the decrease of all the 
analyzed thyroid differentiation markers, although at different extents. Among these, the most 
dramatically down-regulated are the transcription factors Foxe1 and Pax8, Thyroglobulin 
(TG), Sodium/Iodide Symporter (Nis) and Thyroperoxidase (TPO), while TTF-1 and TSH 
receptor show a lower, though statistically significant, decrease (Figure 12C). It is interesting 
to note that none of the down-regulated genes is located on the chromosome 18, indicating 
Thybe1 ability to act in trans. 
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Figure	  12.	  Thybe1	  knockdown	  affects	  thyroid	  differentiation	  in	  vitro.	  A.	  Thybe1	  was	  down-­‐regulated	  in	  FRTL-­‐5	  
transfecting	   100nM	   of	   locked	   nucleic	   acid	   	   targeting	   the	   conserved	   region	   (LNA	   pan	   Tb1),	   in	   red.	   RNA	  was	  
extracted	  48h	  after	  transfection.	  Quantitative	  Real	  Time	  PCR	  for	  Thybe1	  (B)	  and	  thyroid	  differentiation	  markers	  
(C)	  shows	  Thybe1	  Knocking-­‐down	  leads	  to	  the	  down-­‐regulation	  of	  all	  thyroid	  markers	  analyzed.	  All	  values	  are	  
normalized	  to	  ciclofillin	  and	  expressed	  relatively	  to	  LNA	  scramble	  set	  to	  a	  value	  of	  1.	  *,	  P<	  0.05;	  **,	  P<	  0.01;	  
***,	  P<	  0.001.	  
 
 
 
4.4 	  Thybe1	  is	  repressed	  in	  thyroid	  neoplastic	  transformation	  
 
4.4.1 In	  vitro	  Ras	  activation	  suppresses	  Thybe1	  expression	  	  
 
LncRNAs are acquiring an increasingly relevant role in cancer (Huarte, 2015; Lavorgna, 
2016). Alterations and/or increase of lncRNAs are reported to be correlated to cancer 
development, some of which representing a prognostic markers of cancer progress (Gibb et 
al., 2011; Orfanelli et al., 2015; Xia et al., 2017). Being Thybe1 involved in thyroid 
differentiation, we asked if it could be also involved in thyroid cancerogenesis. To this aim 
we used two in vitro models of thyroid transformation with de-differentiantion: ERRasV12 
FRTL-5 and RasV12FRTL-5 cell lines. ERRasV12 FRTL-5 is an inducible system that 
expresses an oncogenic and tamoxifene (4OHT)-inducible form of Ras (ER-RasV12). These 
cells rapidly undergo neoplastic transformation upon 4OHT treatment. The RasV12FRTL-5, 
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instead, express RasV12 constitutively, showing a chronically transformed phenotype (De 
Vita et al, 2005). We evaluated Thybe1 expression by qRT PCR in both systems, revealing 
that both acute and chronic Ras constitutive activation dramatically suppresses lncRNA 
expression compared to the controls, untreated ERRasV12FRTL-5 and WT FRTL-5, 
respectively (Figure 13A,B). 
 
 
            
Figure	   13.	  Thybe1	   is	   repressed	   by	   Ras	   activation.	   Thybe1	   expression	  was	   evaluated	   by	   qrt	   PCR	   analysis,	   in	  
inducible	   ERRasV12FRTL-­‐5	   induced	   with	   1nM	   4OHT	   for	   24h	   (A)	   and	   in	   Ras	   costitutively	   expressing	   FRTL-­‐
5RasV12	  cells	  (B).	  The	  RNA	  expression	  levels	  are	  tubulin-­‐normalized	  and	  relative	  to	  the	  controls	  (left	  bars).	  *,	  
P<	  0.05;	  **,	  P<	  0.01;	  ***,	  P<	  0.001.	  
	  
	  
 
4.4.2 Thybe1	  is	  repressed	  in	  BRaf-­‐driven	  thyroid	  carcinogenesis	  in	  vivo	  	  
	  
To further investigate Thybe1 involvement in thyroid cancer, we exploited an inducible 
thyroid cancer mouse model. In this model, doxycycline (dox) administration induces thyroid 
specific BRafV600E oncogene transcription (Figure 14A), leading to a poorly differentiated 
thyroid cancer (Chakravarty et al., 2011). Mice were treated with dox for one week and 
thyroid lobes were withdrawn and subjected to paraffin inclusion and RNA extraction. QRT 
PCR  (Figure 14B) and in situ hybridization (Figure 14C) showed that Thybe1 is severely 
down-regulated in transformed and poorly differentiated thyroids compared to the normal 
ones.  
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Figure	   14.	   Thybe1	   is	   lost	   during	   BRaf-­‐dependent	   thyroid	   neoplastic	   transformation	   in	   vivo.	   An	   inducible	  
thyroid	  cancer	  mouse	  model	  was	  tested	  for	  Thybe1	  expression.	  A.	  In	  this	  model,	  one	  week	  of	  doxycycline	  (dox)	  
administration	   induces	   a	   specifically	   thyroid	   BRafV600Eexpression,	   causing	   a	   poorly	   differentiated	   thyroid	  
cancer	  (Chakravarty	  et	  al.,	  2011).	  B.	  QRT	  pc	  on	  pools	  of	  control	  (NT)	  and	  dox	  treated	  thyroids	  (+Dox)	  shows	  a	  
dramatic	   reduction	   of	   Thybe1	   levels.	   RNA	   levels	   were	   normalized	   on	   Abelson	   and	   expressed	   relatively	   to	  
controls.	  C.	  Thybe1	   in	  situ	  hybridization	  on	  paraffin-­‐embedded	  control	  and	  treated	  thyroids	  confirms	  Thybe1	  
down-­‐regulation.	  ***,	  P<	  0.001.	  
	  
 
4.4.3 	  Different	  signaling	  pathways	  could	  mediate	  Thybe1	  repression	  in	  
neoplastic	  transformation	  
 
The data obtained in the two experimental models of thyroid cancerogenesis show that either 
Ras, in the in vitro model, or BRaf, in the in vivo model, exert inhibitory effects on Thybe1 
expression. We thus asked if the BRaf pathway is the only Ras-activated pathway responsible 
for the observed Thybe1 repression. To investigate the role of the two main Ras.-downstream 
pathways in down-regulating Thybe1 expression, we pharmacologically inhibited MAPK or 
PI3K pathways during Ras activation in vitro. To this purpose, we treated ERRasV12 FRTL-5 
with tamoxifene (4OHT) together with either MEK inhibitor U0126 or PI3K inhibitor 
LY294002. We evaluated the phosphorylation of ERK and AKT, by western blot analysis, to 
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confirm MEK and PI3K inhibition (Figure 15A). Then we performed a qRT PCR analysis, 
observing that Thybe1 Ras-induced repression is rescued by both BRaf and PI3K inhibition, 
although at different extents (Figure 16B), revealing that both pathways are required, but none 
is sufficient per sé, for Ras-induced Thybe1 repression. Indeed, BRaf inhibition up-regulates 
Thybe1 in basal condition and keeps at bay its repression upon Ras activation, suggesting that 
MAPK pathway exerts a negative effect on Thybe1 expression. Meanwhile PI3K inhibition 
weakly down-regulates lncRNA in non-transformed cells, and partially rescue its suppression 
by Ras (Figure 15B), hinting BRaf and PI3K pathways cooperates to repress Thybe1 
expression in transformed cells.  
 
 
Figure	  15.	  Ras	  Thybe1	  expression	  is	  rescued	  by	  PI3K	  BRaf	  pathways	  inhibition.	  PI3K	  and	  BRaf	  pathways	  were	  
inhibited	  in	  basal	  condition	  (NT)	  and	  after	  Ras	  activation	  (+4OHT),	   in	  ERRASV12	  FRTL-­‐5	  using	  75nM	  LY294002	  
and	   25nM	  U0126	   respectively.	   After	   24h	   RNA	   and	   proteins	   were	   isolated.	   (A).	   AKT	   and	   ERK	   activation	   was	  
checked	  by	  western	  blot	  analysis.	  QRT	  PCR	  were	  performed	  for	  pan	  thybe1	  (B)	  in	  dmso	  control	  (red	  bars),	  PI3K	  
(green	  bars)	  and	  MAPK	  (blue	  bars)	   inhibition,	  revealing	  BRaf	  activity	  per	  sé	   is	  not	  sufficient	  to	  down-­‐regulate	  
Thybe1.	  All	  values	  are	  normalized	  to	  18S	  and	  expressed	  relatively	  to	  dmso	  controls.	  *,	  P<	  0.05;	  **,	  P<	  0.01;	  ***,	  
P<	  0.001.	  
	  
 
 
 
4.4.4 Thybe1	  is	  targeted	  by	  miR182a-­‐5p,	  that	  is	  up-­‐regulated	  in	  thyroid	  
tumorigenesis	  	  
 
To investigate the possible mechanisms of Thybe1 repression in transformation, we asked if it 
could be regulated by a miRNA-mediated mechanism. Since Thybe1 is still poorly 
characterized, we did not find informations about the presence of miRNA-responsive 
elements (MRE) in its transcripts in standard miRNA targets databases. However, the 
RNAHybrid 2.1.2 tool predicted it contains MRE for miRNA182a-5p 
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(https://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid) (Figure 16A). Considering these 
indications, we decided to test Thybe1 responsiveness to this miRNA in vitro. We transfected 
FRTL-5 with miR182a-5p mimic and measured Thybe1 levels, observing that the expression 
of this miRNA (Figure 16B) leads to Thybe1 decrease (Figure 16C). To check if mir182a-5p 
is directly acts on Thybe1 RNA, we tested if miR182a-5p mimic is able to regulate the 
expression of mouse Thybe1 cDNA cloned in an expression vector. We cloned mouse Thybe1 
sequence corresponding to the rat short transcript with the difference of a mouse specific 50bp 
exon, that allowed us to discriminate exogenous from endogenous Thybe1 RNA (Figure 
16D). This transcript was cloned in a pcefl expression vector and co-transfected in FRTL-5 
with the miRNA mimic. Then we specifically measured exogenous Thybe1 expression level 
by qrt PCR, observing that it is down-regulated by miR182a-5p overexpression (Figure 16E). 
MiR182a-5p is already described to correlate with different type of cancer. In particular, it 
was described to be up-regulated in hepatocellular carcinoma, bladder ,breast and prostate 
cancer (Wang at al., 2014; Wang et al 2014; Chiang et al., 2013; Hirata et al., 2012; Peng et 
al., 2013; Wei et al, 2015).  Given the targeting of Thybe1 by miRNA182a-5p, we wondered 
if this miRNA is regulated also in thyroid neoplastic transformation. To answer this question 
we assayed miRNA levels in ERRASV12FRTL-5, RasV12FRTL-5 and in BRaf-dependent 
thyroid cancer mouse model, performing qRT-PCR. Interestingly we observed that miR182a-
5p expression is not affected by Ras acute activation (Figure 17A), whereas it is strongly up-
regulated in the same cell system by chronically active Ras (Figure 17B). Consistently, it is 
also strongly upregulated in undifferentiated BRaf induced thyroid cancer in vivo, (Figure 
17C).  
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Figure	  16.	  Thybe1	  is	  a	  miR182a-­‐5p	  target.	  (A)	  Representation	  of	  the	  miR182a-­‐5p	  MRE	  on	  rat	  Thybe1	  sequence	  
from	  RNAHybrid	  2.1.2	  (https://bibiserv2.cebitec.uni-­‐bielefeld.de/rnahybrid).	  FRTL-­‐5	  were	  transfected	  with	  5nM	  
miR182a-­‐5p	  mimic	  for	  48h.	  	  QRT	  PCR	  for	  miR182a-­‐5p	  (B),	  panTb1	  (C)	  reveal	  miR182a-­‐5p	  effect	  on	  endogenous	  
Thybe1.	  (D)	  Mouse	  Thybe1	  transcript,	  corresponding	  to	  short	  Thybe1,	  except	  for	  a	  50bp	  exon	  (blue	  circle),	  was	  
cloned	   in	   pcefl	   expression	   vector.	   (E)	   FRTL-­‐5	   co-­‐transfected	   with	   0.5γ	   of	   pcefl-­‐muose	   Tb1	   and	   miR182a-­‐5p	  
mimics	  at	  a	  final	  concentration	  of	  25nM.	  48h	  after	  transfection,	  RNA	  was	  isolated	  and	  qRT	  PCR	  confirms	  miRNA	  
action	  on	  Thybe1	  RNA.	  LncRNA	  and	  miRNA	  levels	  were	  normalized	  to	  Ciclofillin	  and	  U6.	  Expression	  values	  are	  
relative	  to	  miRNA	  control	  (left	  bars).	  *,	  P<	  0.05;	  **,	  P<	  0.01;	  ***,	  P<	  0.001.	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Figure	  17.	  miR182a-­‐5p	  is	  up-­‐regulated	  by	  long-­‐term	  oncogene	  activation.	  (A).	  QRT	  PCR	  for	  miR182a-­‐5p	  shows	  
a	  miRNA	  up-­‐regulation	  in	  24h	  induced	  ERRasV12	  FRTL-­‐5	  (+4OHT),	  RasV12	  FRTL-­‐5	  (B)	  and	  doxycycline	  induced	  
BRaf-­‐dependent	   thyroid	   cancer	   (+Dox)	   (C).	   Thyroid	   cancer	   induction	   lasted	  one	  week.	  MicroRNA	   levels	  were	  
normalized	  to	  U6	  and	  are	  expressed	  relatively	  to	  the	  controls	  (left	  bars).	  *,	  P<	  0.05;	  **,	  P<	  0.01;	  ***,	  P<	  0.001.	  
 
 
 
4.4.5 Thybe1	  expression	  is	  suppressed	  in	  human	  thyroid	  cancer	  	  
 
Considering the previous results, we asked if Thybe1 could be repressed also in human 
thyroid cancer. Neoplastic transformation of thyroid follicular cells can give different 
histotypes of thyroid cancer: follicular and papillary, that are well-differentiated cancers and 
anaplastic, that is the most undifferentiated and aggressive one (Nikiforov et al. 2009; Katoh 
et al., 2015). To get an idea of Thybe1 behavior in these different human thyroid cancer 
variants, we analyzed human thyroid cancer cell lines that represent each of these histotypes: 
BCPAP and TCP1 for papillary cancer, WRO for follicular cancer and BHT101, 8505C and 
Cal62 for the anaplastic one (Saiselet et al., 2012). QRT PCR revealed that, compared to 
healthy samples, Thybe1 is severely down-regulated in all tumor cells, without distinguishing 
among different histotypes, differentiation state or aggressiveness (Figure 18). 
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Figure	   18.	  Thybe1	   is	   down	   regulated	   in	   human	   thyroid	   cancer.	  Qrt	  PCR	  was	  performed	  to	  measure	  Thybe1	  
expression	   in	  papillary	   (BCPAP,	  TPC1),	   follicular	   (WRO)	  and	  anaplastic	   (BHT101,	  Cal62,	  8505C)	   thyroid	  cancer	  
cell	  lines,	  after	  normalization	  to	  18S.	  lncRNA	  expression	  is	  relative	  to	  an	  healthy	  samples	  pool.	  *,	  P<	  0.05;	  **,	  P<	  
0.01;	  ***,	  P<	  0.001.	  
 
 
4.4.6 Klhl14	  is	  repressed	  during	  thyroid	  tumorigenesis	  
 
Considering that both Thybe1 and Klhl14 are expressed during thyroid development and they 
seem to be co-regulated, we wondered if also Klhl14 is involved in thyroid neoplastic 
transformation. To answer this question we evaluated its expression in the described models 
of thyroid de-differentiation and tumorigenesis. Interestingly we uncovered that, as observed 
for Thybe1, Klhl14 is severely repressed, in vitro, by Ras activity in ERRASV12FRTL-5 and 
RasV12FRTL-5 (Figure 19A,B). Besides, Klhl14 arises as down-regulated in human cancer 
cell lines with essentially the same trend of Thybe1 (Figure 19C). Moreover, qRT PCR 
(Figure 19D) and in situ hybridization analyses (Figure 19E) evidenced it is suppressed in 
BRaf-dependent thyroid carcinogenesis in vivo. All these data strongly correlate Klhl14 
expression to Thybe1 presence suggesting its direct role in controlling the protein-coding 
gene expression or that the two genes undergo to the same regulatory mechanisms. To 
investigate in this sense we measured by qRT PCR Klhl14 expression in Thybe1 knocking-
down FRTL-5. We found out that Klhl14 is down-regulated by Thybe1 knocking-down 
hinting that the lncRNA presence is required to preserve the protein coding expression (Figure 
20)
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Figure	  19.	  Klhl14	  is	  repressed	  by	  thyroid	  neoplastic	  transformation.	  QRTPCR	  was	  performed	  to	  evaluate	  Klhl14	  
levels	   in	  24h-­‐induced	  ERRasV12	  FRTL-­‐5	  (A),	  RasV12	  FRTL-­‐5	  (B).	  Different	  histotypes	  of	  human	  thyroid	  cancers	  
(C)	  and	  in	  doxycycline	  induced	  BRaf-­‐dependent	  mouse	  thyroid	  cancer	  (+	  Dox)(D).	  RNA	  levels	  are	  normalized	  on	  
Tubulin,	  18s	  and	  Abelson	  respectively.	  In	  A,	  B	  ,C	  and	  D,	  RNA	  levels	  are	  expressed	  relatively	  to	  controls	  set	  to	  a	  
value	  of	  1(left	  bars);	  in	  C	  they	  are	  relative	  to	  a	  pool	  of	  healthy	  samples	  set	  to	  a	  value	  of	  1	  (not	  shown).	  (E)	  Khl14	  
In	   situ	   hybridization	  on	  paraffin	   embedded	   sections	  was	   performed	  on	  dox	   treated	   thyroids.	   Thyroid	   cancer	  
induction	  lasted	  one	  week.	  *,	  P<	  0.05;	  **,	  P<	  0.01;	  ***,	  P<	  0.001.	  
	  
	  
	  	  	  
	  	  	  	  	  	  
	  
	  
Figure	   20.	   Klhl14	  
negatively	   regulated	   by	  
Thybe1	   repression.	  FRTL-­‐5	  
upon	   Thybe1	   interfering,	  
with	   100nM	   LNA	   pan	   Tb1	  
(right	  bar),	  shows	  a	  down-­‐
regulation	   of	   Klhl14	  
expression.	   RNA	   was	  
isolated	   48h	   after	  
transfection.	   mRNA	   levels	  
are	  normalized	  to	  ciclofillin	  
and	   relative	   to	   the	   LNA	  
control.	  *,	  P<	  0.05	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5 Discussion	  
 
In this thesis we report the structural and functional study of a novel gene for a long 
noncoding RNA. The discovery of such gene stems form previous studies of our group aimed 
at investigating the molecular bases of thyroid specification. A screening for genes 
specifically characterizing thyroid development and commitment identified a non-coding gene 
as the most enriched in E10.5 mouse thyroid bud. We named this poorly characterized gene 
Thybe1 (Thyroid bud enriched 1). Thybe1 overlaps, in a head-to head arrangement, with a 
coding gene, Klhl14, also enriched in thyroid bud. The lncRNA chromosome location and its 
overlapping with Klhl14 are conserved in mouse, rat and other species, among which human. 
The evolutionary conservation of such genomic organization strongly suggests that it is 
critical for the function of this pair of genes. To investigate Thybe1 expression profile we 
consulted databases for human tissues and performed an experimental observation for mouse 
tissues. The two approaches revealed that Thybe1 is expressed in many tissues, even if at low 
level, similarly to most of lncRNA (Cabili et al., 2011; Morlando et al., 2014; Marques and 
Ponting, 2009), but more important, it is expressed mainly in thyroid, from very early stage of 
thyroid specification, during embryo development, to adult life, hinting that Thybe1 presence 
is important for gland development and function. Moreover, sequencing of several fragments, 
amplified from adult mouse thyroid and rat thyroid follicular cells, revealed that in addition to 
those already reported in genomic databases, novel splicing transcripts of Thybe1 exist and 
are expressed in thyroid, suggesting that this gene plays a relevant role in this gland, or better 
still, could play more than one role in thyroid development and function. To understand its 
functional role, we knocked-down Thybe1 in normal thyroid cells, obtaining the repression of 
most differentiation markers such as the transcription factors Foxe1, Pax8, Ttf1, 
Thyroglobulin, Sodium-iodide/symporter (Nis) and Thyroid peroxidase (TPO). Such 
widespread effect on differentiation-related genes, could be either a direct effect on each of 
the regulated genes, or more likely could be the indirect consequence of the deregulation of 
one or more transcription factors, whose reduction, in turn, leads to the loss of the other 
markers. However, these data highlight that Thybe1 is able to act in trans on its targets, since 
none of the down-regulated genes is situated near to or on the same chromosome of lncRNA 
locus. 
lncRNAs employ several different molecular mechanisms to activate or repress neighbors 
and/or  distant genes (Wilsuz et al., 2009, Guttman et al., 2012; Scheuermann and Boyer, 
2013; Marchese and Huarte, 2014; Fatica  and Bozzoni, 2014) that could be involved in differ 
 36 
biological events. In particular, an increasing number of studies have outlined the role of 
several lncRNAs in cancer (Huarte, 2015; Lavorgna, 2016). Considering the role of Thybe1 in 
thyroid differentiation, we tested if it could be involved also in loss of differentiation that 
occurs in thyroid cancer development. We thus decided to investigate if Thybe1 is regulated 
by oncogenic transcformation of thyroid cells. To this purpose, we firstly measured its 
expression levels in chronic as well as inducible cellular models of Ras-induced thyroid 
transformation (De Vita et al., 2005). Interestingly we observed that Thybe1 expression is 
dramatically reduced by both acute and chronic oncogenic activation. These results were also 
confirmed in vivo by using a Doxycycline-inducible thyroid cancer mouse model, where 
BRafV600E activation induces a poorly differentiated thyroid cancer (Chakravarty et al., 
2011). We discovered that, in such cancer, Thybe1 levels are considerably lower than in 
normal thyroid, confirming that this lncRNA is strongly repressed during transformation and 
strictly linked to the expression of differentiation-specific genes. Chemical inhibition of both 
BRaf/MAPK and PI3K pathways in cellular models partially rescued the inhibition of Thybe1 
by Ras, showing that activation of BRaf is required but not sufficient per sé for Thybe1 
inhibition. However, during BRaf-dependent thyroid carcinogenesis in vivo, many other 
alterations occur that could lead to the lncRNA repression. 
To test if the observed Thybe1 repression could be mediated by a miRNA-mediated 
mechanism, we looked for MREs on Thybe1 sequence, finding miRNA182a-5p responsive 
elements (https://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid). For this reasons, we validated 
in vitro Thybe1 as a target of this miRNA, transfecting miR182-5p mimics in FRTL-5, 
finding out that it is repressed by the miRNA increase.  Moreover, interestingly, in the 
described in vitro system, miR182a-5p expression is strongly upregulated by chronic 
oncogenic Ras activation, while it is unaffected at early stages of Ras acute induction. miR-
182a-5p was also highly up-regulated in the BRaf induced thyroid cancer in vivo, thus 
supporting the data obtained on in vitro system. This miRNA is already known to be up-
regulated in other type of cancer, although these studies refer to human cancers and no data 
are available on its expression during cancer progression.  Taken together, our data suggest 
that upregulation of miR182a-5p is not an early event in oncogenic transformation of thyroid 
cells, yet its increase can occur in later stages of thyroid cancer development. Thus, the early 
repression of Thybe1 by Ras is likely to be mediated by other mechanisms, while miR182a-
5p could be involved in the long-term Thybe1 inhibition observed both in cultured cells and 
in tumors induced in the mouse model of thyroid cancer. 
Our observations could also lead to speculate that while miR182-increase could be necessary 
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to maintain Thybe1 down-regulated in late stages of cancer development, Thybe1 early 
repression could release a possible sponge effect on miR182a-5p, rendering it available to 
target other RNAs involved in the tumor progression process. To understand what really 
happens, it would be useful to identify Thybe1 promoter and test its activity in transformed 
and/or tumor conditions, and to test the expression of other targets of this miRNA in 
transformed thyroid cells. 
To verify if Thybe1 was also repressed in human thyroid cancer, we measured its levels in 
human follicular, papillary and anaplastic cancer cell lines, uncovering that Thybe1 is 
strongly repressed in all these cells compared to normal samples. Taken together, these data 
demonstrate that Thybe1 is implicated in thyroid cancerogenesis, without differences between 
different histotypes and it is probably lost at early stages of thyroid neoplastic transformation. 
Thybe1 has another interesting feature that is the overlap with the protein-coding gene 
Klhl14, also enriched in thyroid bud. Their head-to-head arrangement allowed us to classify 
Thybe1 as a Natural Antisense Transcript (NAT). NATs are known to regulate the expression 
of the corresponding protein-coding gene in positive or negative way (Wilsuz et al. 2009; 
Ørom et al., 2010; Boque-Sastre et al., 2015). Given this relationship, we investigated Klhl14-
Thybe1 expression correlation. We analyzed Klhl14 expression profile observing that it is 
expressed during thyroid bud development from E10.5 to mouse adult gland, similarly to the 
lncRNA. Moreover it shows a tissue expression trend similar to that of Thybe1, being mostly 
expressed in thyroid.  Interestingly we also observed that, like Thybe1, Klhl14 is strongly 
down-regulated by thyroid transformation and tumorigenesis in vitro and in vivo. These data 
suggest that Thybe1 and Klhl14 are regulated by the same factors and/or Thybe1 positively 
regulates Klhl14 expression. The down-regulation of Klhl14 upon Thybe1 knocking-down, 
observed in cultured cells, supports the second hypothesis, also suggesting that it is not 
Thybe1 transcription to induce Klhl14 expression. NATs are described to positively regulate 
the overlapping protein-coding gene by recruiting the transcription complex to their own 
promoter and so promoting also the transcription on the opposite strand. Others lncRNAs act 
as so called “scaffold RNAs”, binding and stabilizing the protein of their gene target ( Wilsuz 
et al., 2009, Scheuermann and Boyer, 2013; Marchese and Huarte, 2014). In our model, LNA 
mediated Thybe1 decrease does not affect the lncRNA transcription, but it down-regulates 
Klhl14 mRNA. Hence, it is not its transcription per sé to promote Klhl14 expression, but it 
could act in cis enhancing transcription factors binding to klhl14 promoter (Boque-Sastre et 
al., 2015). Moreover, Thybe1 knocking-down also reduces mRNA levels of several thyroid 
markers, suggesting Thybe1 works, in trans, on the targeted mRNAs. Indeed, if Thybe1 acted 
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binding the proteins, we would not see negative effects on mRNAs. Thybe1 could promote its 
target translation and/or prevent their degradation, or act as a guide for the transcription 
complex on the targeted promoters. Furthermore, different transcripts could play different 
roles. Indeed, we identified several and not reported transcripts and our preliminary data show 
that previously uncharacterized thyroid transcripts exist, suggesting the possibility that this 
lncRNA could play a very wide range of roles. This issue is still unexplored and remains a 
very interesting topic to deepen. Finally, to shed lights on Thybe1 role in thyroid 
differentiation, we are generating a conditional knockout mouse that will lost Thybe1 
expression only in thyroid gland, that will allow us to study the resulting phenotype to clarify 
its exact role in gland development. 
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6 Conclusions	  
 
In this work we characterized for the first time a novel long non-coding RNA involved in 
thyroid differentiation that we named Thybe1. More interesting, we demonstrated Thybe1 is 
dramatically repressed by thyroid carcinogenesis highlighting an essential role of this long 
non-coding RNA in maintaining thyroid differentiation state.  
All these data prompt to deepen the knowledge about Thybe1 functions and its implication in 
thyroid development and carcinogenesis. Indeed, our data hint it could represent an early 
marker of both thyroid specification and neoplastic transformation. Hence, its alterations, 
during organogenesis, could lead to different thyroid development defects implicating many 
clinical outcomes such as congenital hypothyroidism. Furthermore, although further studies 
are required to clarify this lncRNA role in thyroid differentiation and transformation 
processes, clinical investigations could elucidate if Thybe1 could cover a prognostic role in 
thyroid cancer. For these reasons it could be very interesting and useful to understand 
molecular mechanisms and all the possible clinical correlation and implications of this novel 
candidate gene playing a role in thyroid differentiation and cancer. 
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